Emily Kaine, MD, senior VP global health and manufacturing services at US Pharmacopeia (USP), discusses the work USP is engaged in to strengthen the global supply chain of quality-assured medicines and build manufacturing capabilities for new and innovative medicines.
Ashley Woodyard, a PharmD candidate at the Touro University California College of Pharmacy in Vallejo and co-author of an article in the January 2022 issue of Pharmacy Times®, discussed the article and the benefits of pharmacy technicians as vaccine administrators.
In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.
Experts in gynecologic oncology provide insight on available patient assistance programs to help lower costs of PARP inhibitors for the treatment of ovarian cancer, and how pharmacists can aid in obtaining this information.
Anna Legreid Dopp, PharmD, the Senior Director of Clinical Guidelines & Quality Improvement at ASHP, and Bayli Larson, PharmD, the Strategic Initiatives Associate at ASHP, discuss the grant the ASHP received from the American Rescue Plan.
Abemaciclib (Verzenio) was recently approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.
Ron Lanton III, Esq, principal at Lanton Law, said entrepreneur Mark Cuban's new venture into the pharmacy field is very interesting, although it maybe just another player in the mail-order pharmacy market.
Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discusses some trends and predictions for health care IT this year and on into the future.
Brian Thornley, the Associate Vice President of Supply Excellence, Innovation and Digital Strategy at Merck, discusses what makes blockchain unique and what it could mean down the road for pharmacies.
Mitchel Rothholz, RPh, MBA, chief of governance and state affiliates at the American Pharmacists Association (APhA) and executive director of the APhA Foundation, discusses the results of a nationwide survey of pharmacists during the ongoing pandemic.
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Drs Angela Rasmussen and Donald Alcendor detail the roadblocks facing COVID-19 booster shots.
Expert panel discusses the current state of the pharmacy technician role, how COVID-19 changed the perception of pharmacy technicians, and updates across the legislative and regulatory landscape for pharmacy technician–administered tests and vaccines.
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses projections for inclisiran’s use in clinical and pharmacy settings.
Having such a program spearheaded by pharmacists has helped show the public the vital roles that pharmacists play.
Kirollos Hanna, PharmD, BCPS, BCOP, discusses clinical trial data for second-generation BTK inhibitors for chronic lymphocytic leukemia.
Anthony Perissinotti, PharmD, BCOP, provides an overview of the available treatment options in chronic lymphocytic leukemia, highlighting the role of first-generation BTK inhibitors.
In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.
Javier Pinilla-Ibarz, MD, PhD; Lisa Nodzon, PhD, ARNP, AOCNP; and Katie Tobon, PharmD, BCOP, describe the incidence of CLL and discuss factors that may increase the risk of disease.
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses the burden of ASCVD in the country today.
Sarah Hayward, PharmD, BCOP, leads the discussion on strategies used to keep the healthcare team well-informed and up to date on emerging data about PARP inhibitors for the treatment of ovarian cancer.
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discussed inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discussed what the impact of the pandemic has been on the advancement of data interoperability in health care.
Donald Alcendor, PhD, and Angela Rasmussen, PhD, explain how to discuss the importance of COVID-19 booster shots with patients.
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran, discussed the trial results assessing the efficacy and safety of inclisiran for patients with atherosclerotic cardiovascular disease.
Jeff Goad, PharmD, MPH, and Angela Rasmussen, PhD review the population trends of COVID-19 booster shots.
Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discusses what data interoperability is and what it looks like within a pharmacy context.
Future studies are necessary to continue evaluating the true benefits of dupilumab in conditions like atopic dermatitis.
An explanation of the risks associated with COVID-19 booster shots.
